Medical Strategy

Medical Strategy - Investments & Acquisitions

Show Real Data Medical Strategy Investments
See all Recent Investments
Date Company Round Amount Co-investors
2010-05-19NOXXON PharmaSeries D$42MAndera Partners, Berlin Capital Fund, Commerzbank - Equity Markets and Commodities Unit, DEWB, Dieckell Vermogensverwaltung, Dow Venture Capital, Excalibur Group, FCP OP MEDICAL BioHelth-Trends, GBK Beteiligungen, Hannover Finanz, HF Fonds VII Unternehmensbeteiligungs, IBB Beteiligungsgesellschaft, IBG Beteiligungsgesellschaft, KfW Mittelstandsbank, Oppenheim Pramerica Asset Management, Peppermint VenturePartners, Pfizer Venture Investments, Provinzial Beteiligungsgesellschaft, Seventure Partners, Sofinnova Partners, TVM Capital Life Science, VC Venture-Beteiligungen, and WeHaCo Unternehmensbeteiligungs
2008-02-15Auris MedicalSeries B$16.14MAGF Private Equity, Lacuna Apo Biotech Subfund, and Zurcher Kantonalbank
2007-03-20Neose TechnologiesUnattributed VC - IV$43.26MAbingworth, Baker Brothers Investments, Balyasny Asset Management, Bellevue Asset Management, Bristol Capital Advisors, Domain Associates, Downsview Capital, Dp V Associates Lp, Iroquois Capital Group, MHR Fund Management, MPM Capital, Oppenheim Pramerica Asset Management, OrbiMed Advisors, Paramount Capital Asset Management, Potomac Capital Management, Tang Capital Management, and Visium Asset Management
2007-02-09Ziopharm OncologyPIPE - II$30.88MAWM Investment Company, Diamondback Capital Management, Essex Woodlands, FCP OP MEDICAL BioHelth-Trends, Henderson Global Investors, J.P. Morgan Chase & Co., LBI Group, Millennium Management, Oppenheim Pramerica Asset Management, Panacea Asset Management, PHARMA/wHEALTH, ProQuest Investments, and PTV Sciences
2006-05-05Ziopharm OncologyPIPE$37MAbu Dhabi Investment Authority, Andrew Carter Capital, Broadlawn Capital Management, Bushido Capital Partners, Clarion Capital Partners, Cycad Group, Dorset Management Corporation, Downsview Capital, Emerging Technology Center, FCP OP MEDICAL BioHelth-Trends, H & A Lux VCH Expert Biotech, Hackney Group, Hauck & Aufhauser, Henderson Global Investors, Highbridge Capital Management, Hollis Capital Management, Iroquois Capital Group, Knott Partners, LBI Group, Lewis Asset Management, Mehta Partners, Millennium Management, Mosaix Ventures, Panacea Asset Management, ProQuest Investments, Quantitative Bioequities Management, Riverside Contracting, Sterling Securities International, and Visium Asset Management
See all 7 investments